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ABSTRACT:
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal 
human malignancies worldwide. Advanced or recurrent HCC is frequently resistant 
to conventional chemotherapeutic agents and radiation. Therefore, targeted agents 
with tolerable toxicity are mandatory to improve HCC therapy and prognosis. In this 
neoplasia, the PI3K/Akt signaling network has been frequently shown to be aberrantly 
up-regulated. To evaluate whether Akt could represent a target for treatment of HCC, 
we studied the effects of the allosteric Akt inhibitor, MK-2206, on a panel of HCC cell 
lines characterized by different levels of Akt-1 activation. The inhibitor decreased 
cell viability and induced cell cycle arrest in the G0/G1 phase of the cell cycle, with a 
higher efficacy in cells with hyperphosphorylated Akt-1. Moreover, MK-2206 induced 
apoptosis, as documented by Annexin V labeling, and also caused autophagy, as 
evidenced by increased levels of the autophagy marker LC3A/B. Autophagy was 
shown to be a protective mechanism against MK-2206 cytotoxicity. MK-2206 down-
regulated, in a concentration-dependent manner, the phosphorylation levels of Akt-
1 and its downstream targets, GSK3 α/β and FOXO3A. MK-2206 synergized with 
doxorubicin, a chemotherapeutic drug widely used for HCC treatment. Our findings 
suggest that the use of Akt inhibitors, either alone or in combination with doxorubicin, 
may be considered as an attractive therapeutic regimen for the treatment of HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
deadly cancers worldwide with only few therapeutic 
options for patients with advanced disease, since it usually 
develops on the background of chronic liver disease and 
conventional anticancer therapies are not effective [1]. For 
example, the patient response rate to doxorubicin, the most 
widely used chemotherapeutic agent for  HCC, is between 
2% and 10% [2]. Therefore, major efforts are being made 
to develop rationally targeted therapies against altered 
signaling cascades that sustain HCC cell proliferation, 
survival, and drug-resistance. Sorafenib, a Raf kinase 
inhibitor, became the first drug to receive FDA approval 
for HCC, after being demonstrated to increase post-
diagnosis mean survival of patients with advanced HCC 
and cirrhosis from approximately 8 to 11 months [3-5].
These results have triggered the search for other additional 
molecular targets to further improve HCC patient survival 
[6, 7]. 
The PI3K/Akt signaling pathway plays a central 
role in regulating cell proliferation, migration, survival 
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and angiogenesis [3, 8]. Activation of phosphoinositide 
dependent kinase  1 (PDK1) and Akt by class IA PI3Ks 
(which includes PI3K p110α) is negatively regulated 
by PTEN, that converts phosphatidylinositol-(3,4,5)-
trisphosphate [PtdIns(3,4,5)P3] to phosphatidylinositol-
(4,5)-bisphosphate [PtdIns(4,5)P2] [9]. However, this 
signaling pathway is involved not only in physiological 
processes, but also in the development of cancers, 
including HCC [8, 10-12]. In HCC, deregulation of the 
PI3K/Akt pathway is the result of multiple molecular 
mechanisms, including activating mutations of PI3K 
p110α catalytic subunit, loss of expression of its negative 
regulator, the lipid phosphatase and tensin homolog 
deleted on chromosome ten (PTEN) or aberrant activation 
of receptor tyrosine kinases [13]. PTEN was demonstrated 
to be involved in HCC pathogenesis and in increased 
tumor grade and poor prognosis. [14, 15]. 
Phosphorylation of Akt at Ser473 was detected 
in up to 71% of HCC samples, and was associated with 
invasion, metastasis and vascularization [16]. The same 
authors, using a panel of HCC cell lines, demonstrated that 
Akt-1 is widely represented and is the most abundantly 
expressed Akt isoform. Activated Akt is known to inhibit 
apoptosis through its ability to phosphorylate several 
targets, including BAD, FoxO transcription factors, Raf-
1 and caspase-9, which are critical for cell survival [17]. 
However, the clinical relevance of the PI3K/Akt 
pathway as an innovative target in HCC and its therapeutic 
potential remain to be further elucidated, in parallel with 
our growing knowledge of the role of signaling pathways 
and their alterations involved in HCC pathogenesis. 
MK-2206 is a novel, orally active, allosteric 
Akt inhibitor which is being tested both in preclinical 
settings and clinical trials as an anticancer agent. It can 
synergistically enhance the antitumor effect of some 
conventional chemotherapeutic drugs and molecular 
targeted agents in lung cancer, ovarian cancer, breast 
cancer and acute leukemias [18, 19]. 
In this study, we analyzed the cytotoxic activity of 
MK-2206 in HCC cell lines displaying different levels of 
Akt-1 phosphorylation. We documented that MK-2206 
was much more cytotoxic to cell lines (Mahlavu and 
SNU475) displaying higher levels of Akt-1 activation 
than to cell lines with lower levels of activated Akt-1 
(PLC, SNU387). Treatments of HCC cells with MK-
2206 caused cell cycle arrest in the G0/G1 phase of the 
cell cycle, induced apoptosis and autophagy. However, 
autophagy was a protective mechanisms against MK-2206 
cytotoxicity. Moreover, MK-2206 potently synergized 
with doxorubicin in Mahlavu cells. These findings 
suggested that targeting Akt-1 with MK-2206, alone or 
in combination with conventional chemotherapy, may 
represent a new promising therapeutic approach in the 
treatment of HCC with hyperphosphorylated Akt-1.
RESULTS
Akt-1 phosphorylation levels in HCC cell lines are 
related to PTEN expression
We first analyzed the basal expression of Akt-1 and 
its phosphorylation status on Ser473 on a panel of human 
Figure 1: Different levels of Akt-1 phosphorylation are detected in HCC cell lines and correlate with cell cycle block 
induced by MK-2206. (A) Western blot analysis for Ser 473 p-Akt-1, total Akt-1 and PTEN in HCC cell lines. Fifty µg of protein was 
blotted to each lane. An antibody to β-actin documented equal lane loading. (B) Cell cycle in PLC and Mahlavu cells, treated with MK-
2206, was analyzed by the MuseTM Cell Analyzer, according to the instrument protocol. The results are the mean ± s.d. of three different 
experiments. Asterisks indicate significant differences (p<0.05) in comparison with control (CTRL).
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HCC cell lines (PLC, SNU387, Mahlavu, SNU449 and 
SNU475 cells). Akt-1 total amount was similar in the 
five cell lines examined (Fig. 1A). On the contrary, the 
phosphorylation status of the protein, as documented 
by Western blot analysis with an antibody to Ser 473 
p-Akt-1, showed relevant differences: in PLC cells a 
negligible phosphorylation level of Akt-1 was observable, 
in SNU387 cells only a slight Akt-1 phosphorylation was 
detectable, whereas a significant Akt-1 phosphorylation 
was detectable in Mahlavu, SNU449 and SNU475 cells. 
SNU387 cells in comparison with PLC cells showed a 
decrease of PTEN protein. A lower expression in SNU449 
or loss of PTEN protein in Mahlavu and SNU475 
cell lines, respectively, was associated with Akt-1 
hyperphosphorylation. Therefore, our initial observations 
suggested that Mahlavu, SNU449 and SNU475 cells 
displayed hyperactivated Akt-1 when compared with PLC 
and SNU387 HCC cell lines. 
MK-2206 blocks in the G0/G1 phase of the cell 
cycle HCC cells with hyperphosphorylated Akt-1
Given the importance of the PI3K/Akt signaling 
pathway in the regulation of cell proliferation [20], the 
effects of MK-2206 on cell cycle progression of HCC 
cells were investigated. The analysis was carried out on 
PLC and Mahlavu cells, to compare the drug effect in an 
Akt-1 non-hyperphosphorylated cell line versus an Akt-1 
hyperphosphorylated one. Both cell lines were treated 
with increasing concentrations of MK-2206 for 24h, after 
which time the cells were harvested, fixed and stained with 
Propidium Iodide (PI) for the MuseTM Cell Analyzer. The 
analysis documented a not significant increase in the G0/ 
G1 phase of the cell cycle in PLC cells whereas a striking 
concentration-dependent increase in the G0/G1 phase of the 
cell cycle and a concomitant decrease in the S and G2/M 
phases were detected in Mahlavu cells (Fig. 1B).  
Real-time, dynamic monitoring of cell growth in 
HCC cells treated with MK-2206
To further analyze the activity of MK-2206 in HCC 
cells, we used a novel cell surveillance system to monitor 
the dynamic changes in cell growth based on the electrical 
impedance measurement technique (xCELLigence 
System). The xCELLigence System allowed us to study 
the effects of MK-2206 on HCC cells by a label-free 
and a real-time native approach. After the setting of the 
proliferation standards of PLC, SNU387, Mahlavu and 
SNU475 cells, we studied the cytotoxicity of the inhibitor 
at increasing concentrations. The plots demonstrated the 
concentration- and time-dependent cytotoxic effect of 
MK-2206 on PLC and Mahlavu cells (Fig. 2A) and the 
IC50 values of the drug at 24h of treatment was obtained 
by this technique: 18 μM for PLC, 16 μM for SNU387, 
6.4 μM for Mahlavu and 6.7 μM for SNU475 cells, 
Figure 2: Dynamic monitoring of cell growth in HCC cells with the xCELLigence System. (A) Concentration- and time- 
dependent cytotoxic effects of MK-2206 in PLC and Mahlavu cells after MK-2206  treatment, analyzed using the xCELLigence System. 
(B) IC50 values of MK-2206 at 24h of treatment in PLC, SNU387, Mahlavu and SNU475 cell lines. (C) CI values in PLC, SNU387, 
Mahlavu and SNU475 cell lines after 24h of treatment with MK-2206. One representative of three different experiments is shown.
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respectively (Fig.2B). 
We also analyzed the Cell Index after 24h of 
treatment with MK-2206 at different concentrations. As 
shown in Fig. 2C, Mahlavu and SNU475 cells were more 
sensitive to MK-2206 than PLC and SNU387 cells. It is 
noticeable a correlation between the lower concentration 
of drug needed to attain IC50 values and the levels of 
hyperphosphorylated Akt-1 in Mahlavu and SNU475 cells.
MK-2206 induces both apoptosis and autophagy 
in HCC cells
In order to establish whether decreased cell growth 
was related to apoptosis in HCC cell lines, we analyzed 
programmed cell death by Annexin-V/7-AAD-assay 
using the MuseTM Cell Analyzer. PLC and Mahlavu cells 
were treated with increasing concentrations of MK-2206 
for 24h and then analyzed for Annexin-V labeling. MK-
2206 induced concentration-dependent apoptosis in both 
cell lines. However, at 5 µM concentration of MK-2206, 
apoptosis was 11.7% in PLC cells, (Fig. 3A), whereas it 
reached 51.6 % in Mahlavu cells (Fig. 3B). 
Recently, the inhibition of  Akt has been shown to 
possess autophagy-inducing effects in addition to pro-
apoptotic effect [21]. Induction of autophagy can promote 
either cell survival or cell death, depending on the cellular 
context and/or initiating stimulus [22]. 
To examine the effects of MK-2206 on autophagy in 
human HCC cell lines, we treated Mahlavu and SNU475 
cell lines with the Akt inhibitor and then we assessed the 
conversion of LC3A/BI to LC3A/BII, as an autophagy 
marker [23-25]. Western Blot analysis documented, after 
4h of treatment with MK-2206, an increase in the lipidated 
form of LC3A/B (LC3A/BII) in the two cell lines (Fig. 
3C). To understand if autophagy was either a cell survival 
or a cell death mechanism, we inhibited this process using 
the lysosome inhibitor chloroquine [26] and then measured 
the Cell Index in Mahlavu cells. Chloroquine alone did not 
affect Mahlavu cell growth, even at the concentration of 10 
µM. However, when Mahlavu cells were simultaneously 
treated with chloroquine and MK-2206, administered at 
the IC50 value, they became more sensitive than to MK-
2206 alone, i.e. MK-2206 became more cytotoxic in the 
presence of 10 µM chloroquine (Fig. 3D). 
MK-2206 regulates PI3K/Akt signaling and 
induces MEK/ERK1/2 upregulation 
In order to investigate the effects of MK-2206 
on Akt-1 and its downstream targets, we analyzed the 
Figure 3: MK-2206 induces apoptosis and autophagy in HCC cell lines. (A, B) Analysis of Annexin-V positive cells after 
MK-2206 treatment using the MuseTM Cell Analyzer in PLC and Mahlavu cells. The analysis was performed after 24h of treatment 
with increasing concentrations of MK-2206. The results are the mean ± s.d. of three different experiments. Asterisks indicate significant 
differences (p<0.05) in comparison with control (CTRL). BK represents the unstained samples. In both cell lines the apoptotic process 
was further increased when the drug was administered at the concentration of 10 µM. (C) Western blot analysis documenting increased 
expression of the fast-migrating (lipidated) form of LC3A/B in Mahlavu and SNU475 cell lines treated with MK-2206. An antibody to 
β-actin documented equal lane loading. (D) xCELLigence System analysis documenting the effects of chloroquine (CQ) on growth of 
Mahlavu cells treated with MK-2206. One representative of three different experiments is shown.
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modulation of the PI3K/Akt pathway in Mahlavu and 
SNU475 cells. After a 4h incubation with MK-2206, 
a concentration-dependent decrease in p-Akt-1 levels 
was detected in all cell lines (Fig.  4A). The decrease 
was already detectable at 1 μM. In contrast, total Akt-1 
levels were not affected by MK-2206. Akt inhibition had 
functional consequences on the phosphorylation of two 
well-established Akt substrates, GSK3-α/β and FoxO3A. 
Both proteins displayed dephosphorylation at amino acidic 
residues (Ser 21/9 for GSK3-α/β and Thr-32 for FoxO3A) 
that are targeted by Akt. The amounts of  total GSK3- α/β 
and FoxO3A were unchanged. 
Compensatory activation of parallel signaling 
through the MEK/ERK1/2 pathway in response to PI3K/
Akt inhibition, is an emerging theme in cancer cell 
signal transduction. Indeed, several recent reports have 
highlighted the importance of functional cross talks 
between the MEK/ERK1/2 and PI3K/Akt signaling 
networks, in response to individual pathway inhibitors 
[20, 27-31]. 
For this reason, we examined the status of p-ERK1/2 
phosphorylation in both Mahlavu and SNU475 cell lines, 
after treatment for 24h with increasing concentrations of 
MK-2206. In both cell lines, we detected a concentration-
dependent increase in the phosphorylation levels of 
p-ERK1/2, whereas the total protein amount remained 
unchanged (Fig. 4B).
To establish if this activation was dependent on 
MEK activity, we inhibited MEK in Mahlavu cells with 
the MEK-specific allosteric inhibitor, AZD6244 [32]. As 
shown in Fig. 4C, the drug completely prevented the MK-
2206 induced up-regulation of p-ERK1/2.
Furthermore, we performed an MTT assay to 
determine if a combined treatment (MK-2206 plus 
AZD6244) would further decrease cell viability at 24h. 
When the two drugs were administered together, cell 
viability decreased significantly when compared with 
either drug alone (Fig. 4D).
Down-regulation of Akt-1 reduces MK-2206 
cytotoxicity in Mahlavu cells  
To further evaluate the inhibition of Akt-1 signaling 
as a major molecular target responsible for the effects 
of MK-2206 in HCC cells, we down-regulated protein 
expression of Akt-1 in Mahlavu cells by using siRNA. 
After 24h of transfection, we first examined by Western 
blotting the decrease of Akt-1 expression. As shown in Fig. 
5A, Akt-1 siRNA significantly reduced the expression of 
Akt-1 protein. Down-regulation of Akt-1 was not further 
increased by administration of MK-2206.
Then, we studied cell growth with the xCELLigence 
System in both non-transfected and transfected cells. After 
6h from transfection, MK-2206 was added in both non-
transfected and transfected cells for an additional 18h 
Figure 4: Effects of MK-2206 on the phosphorylation levels of key Akt substrates and ERK 1/2. (A) Western blot 
analysis for phosphorylated/total Akt-1, GSK3-α/β and FoxO3A in Mahlavu and SNU475 cells treated with increasing concentrations 
of MK-2206. 50 µg of protein was blotted to each lane. β-actin served as a loading control. (B) Western blot analysis for phosphorylated 
ERK1/2 and total ERK1 in Mahlavu and SNU475 cells treated with increasing concentrations of MK-2206. 50 µg of protein was blotted 
to each lane. (C) Western blot analysis for phosphorylated ERK1/2 and total ERK1 in Mahlavu cells treated for 24h with MK-2206 (5 
µM) and/or AZD6244 (500 nM). (D) Cell viability analysis by MTT assays of Mahlavu cells treated for 24h with MK-2206 (5 µM) and/or 
AZD6244 (500 nM). The results are the mean ± s.d. of three different experiments. The asterisk indicates significant differences (p<0.05) 
in comparison with control (CTRL) and single treatments.
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(Fig. 5B and C). Interestingly, the addition of MK-2206 
to 6h transfected cells did not decrease their growth that 
resulted, on the contrary, higher than the siRNA treated 
sample. Therefore, the removal of MK-2206 target by 
transfection resulted in a lower drug cytotoxicity when 
compared with the drug-untreated transfected samples 
(Fig. 5B and C). 
MK-2206 synergizes with doxorubicin in Mahlavu 
cells
We then examined whether MK-2206 could 
synergize with the anthracycline antibiotic doxorubicin, 
since this drug is frequently included in different protocols 
to treat HCC. Mahlavu cells were treated with doxorubicin 
at a single concentration (0.1 μM) and with MK-2206 at 
two different concentrations (0.5 and 1.5 μM) and the 
synergistic effects of the combination were monitored after 
48h or 72h of treatment using the xCELLigence System 
and by analyzing the Cell Index (Fig.6A and B). We 
could observe a synergistic effect of the combined drug 
treatment in suppressing cell proliferation and viability, 
more evident at the higher (1.5 μM) concentration of MK-
2206 (Fig.6A and B). 
DISCUSSION 
HCC is the third most common cause of cancer-
related death worldwide [33]. Although patients with 
early-stage disease have a good prognosis, there has been 
no effective therapy available for those with advanced 
disease. Thus, treatment of HCC remains an urgent health 
concern [34].
Activation of the PI3K/Akt signaling pathway 
through mutations and/or inactivation of key pathway 
components occurs in various malignancies, including 
HCC [35]. Several mechanisms may be responsible 
for the activation of PI3K/Akt in HCC cells. The high 
frequency of the PI3K p110α gene (PIK3CA) mutations 
and/or its up-regulation in patients with a shorter survival 
is responsible for the Akt hyperactivation found in HCC 
with poor prognosis [20]. Moreover, impaired expression 
of PTEN could be involved in the regulation of PI3K/Akt 
activity. Indeed, activation of Akt signaling and a reduced 
expression of PTEN has been reported in 40–60% of 
human HCC [14]. Recent studies have demonstrated that 
PTEN expression plays a critical role in HCC progression 
and patient survival. Patients with a high PTEN expression 
had a significantly better overall survival than patients 
with a lower expression [36].
On the other hand, activated ERK1/2 and its 
downstream effectors were strongly upregulated in the 
miscroscopic, residual lesions in the livers of Akt/Ras 
mice [13], thus indicating the potential existence of a 
functional crosstalk between PI3K/Akt and Ras/Raf/MEK/
ERK1/2 pathways along hepatocarcinogenesis, whose 
inhibition might be highly beneficial for the treatment of 
Figure 5: Down-regulation of Akt-1 reduces MK-2206 cytotoxicity in Mahlavu cells. (A) Western blot analysis for Akt-1 in 
cells transfected for 24h with siRNA to Akt-1 and effects of MK-2206. LIPO: cells treated with Lipofectamine alone. β-actin served as a 
loading control. (B, C) xCELLigence System analysis documenting the effects of MK-2206 (18h of treatment) on cell growth, starting after 
6h of transfection with siRNA to Akt-1. In (B) one representative of three different experiments is shown. In (C) the results are the mean ± 
s.d. of three different experiments. The asterisk indicate significant differences (p<0.05). 
Oncotarget 2013; 4: 1496-15061502www.impactjournals.com/oncotarget
HCC patients.
Although some preclinical studies have 
demonstrated that PI3K/Akt inhibitors such as perifosine, 
LY294002 and wortmannin displayed anti-HCC activity, 
no studies have been conducted so far at the clinical level. 
In this study, we aimed to investigate the potential 
therapeutic activity of the novel oral allosteric Akt 
inhibitor, MK-2206. In a recent investigation, the 
combination of the multikinase inhibitor Sorafenib 
and MK-2206 overcame the resistance of HCC cells 
to Sorafenib at clinically achievable concentrations, 
suggesting the potential use of this treatment in HCC 
patients [37]. Here, we demonstrated that MK-2206, as 
a single agent, decreased the growth of HCC cell lines 
in a concentration-dependent manner, blocked the cells 
in G0/G1 phase of the cell cycle and induced apoptosis. 
In particular, the activity of the drug on cell proliferation 
was analyzed through a novel, innovative technology 
referred to as xCELLigence System, where proliferation 
of cells, as a first step, and the cytotoxicity of the drug as 
a second step, were monitored in real-time through gold 
microelectrode arrays on a glass substrate in the bottom 
of 96 E-Plates, specific for the system. The cytotoxic 
activity of MK-2206 was more potent in cell lines with 
higher levels of p-Akt1 (Mahlavu, SNU475) than in cells 
with lower p-Akt1 levels (PLC, SNU387). This finding 
demonstrated the selectivity of the inhibitor. 
An interesting observation is that MK-2206 also 
induced autophagy in HCC cells, as documented by the 
increased expression of lipidated LC3A/B (LC3A/B-II) 
in a concentration-dependent manner. The correlation 
between autophagy and tumorigenesis has been explored 
extensively, but whether autophagy acts as a pro-
tumorigenic or anti-tumor player in tumor development 
and cancer therapy is still unclear [38, 39]. 
The process of autophagy is characterized by the 
formation of the autophagosome, a double membrane 
structure that sequesters the target organelles/proteins and 
then fuses with endo/lysosomes, where the content itself 
and the autophagosome major component, LC3A/B, are 
degraded [40, 41]. Autophagy has been demonstrated 
to be required for continued cell growth in pancreatic 
cancers [42]. Accumulating evidence demonstrated also 
that suppression of the proteins involved in autophagy, 
such as Beclin-1 and Atg-5, could cause acceleration of 
tumorigenesis [38]. We documented that chloroquine, 
an autophagy inhibitor, sensitized Mahlavu cells to the 
cytotoxic effects of MK-2206. This finding suggests that 
in HCC cells autophagy could have a tumor protecting 
role when neoplastic cells are treated with Akt inhibitors. 
In this connection, it is worth remembering here that it 
has previously been reported that MK-2206 induces 
autophagy in human glioma cells and this protected tumor 
cells against apoptosis [18]. Therefore, the inclusion of 
autophagy inhibitors could be considered in future HCC 
therapeutic protocols based on Akt inhibitors. Indeed, a 
number of clinical trials are now revealing the promising 
role of chloroquine as a novel antitumor drug [43].
In Mahlavu and SNU475 cell lines, MK-2206 
dephosphorylated Akt-1 on Ser 473 and its downstream 
targets, GSK3-α/β and FoxO3A. However, MK-2206 
increased the phosphorylation levels of ERK 1/2, through a 
MEK-dependent mechanism, as the hyperphosphorylation 
was blocked by the MEK inhibitor, AZD6244. ERK 1/2 
hyperphosphorylation acted as a protective mechanism 
against MK-2206 cytotoxicity, as the MK-2206/AZD6244 
combined treatment was more cytotoxic to Mahlavu cells 
than either treatment alone. 
To further delineate the inhibition of Akt signaling 
as a major molecular target responsible for the effects 
of MK-2206 in HCC cells, we down-regulated protein 
expression of Akt-1 in Mahlavu cells by siRNA 
transfection. The viability of transfected cells with Akt-
1 down-regulation, was higher than control samples after 
MK-2206 treatment, implying that removal of the MK-
2206 target by transfection could result in a lower drug 
cytotoxicity. 
Conventional anticancer therapies for the treatment 
Figure 6: MK-2006 displays synergistic cytotoxic 
effects with doxorubicin in Mahlavu cells. (A, B) 
xCELLigence System analysis showing the synergistic effects 
of a combined treatment consisting of doxorubicin (DOXO) at 
a single concentration (0.1 μM) and MK-2206 at two different 
concentrations (0.5 and 1.5 μM). The CI was monitored after 
48h of treatment. In (A) one representative of three different 
experiments is shown, while in (B) the results are the mean ± 
s.d. of three different experiments. Asterisks indicate significant 
differences (p<0.05) in comparison with single treatments.
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of HCC are not effective [1]. Considering the very low 
response rate to doxorubicin, perhaps the most widely 
used traditional chemotherapeutic drug used in HCC 
patients [2], it appeared of interest to explore the efficacy 
of the combination of chemotherapy with other selective 
agents targeted to specific signal transduction effectors. 
We demonstrated in this work that MK-2206 was able 
to synergize with doxorubicin. Analysis of the results 
demonstrated in Mahlavu cells a synergistic effect of the 
combined treatment in suppressing cell proliferation. 
In conclusion, our findings strongly suggest that 
MK-2206, either alone or combined with traditional 
chemotherapeutic drugs, could be a valuable compound 
for treating HCC patients displaying activation of PI3K/
Akt signaling and who are still facing a very poor 
prognosis. 
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium (DMEM), 
RPMI-1640 medium, fetal bovin serum (FBS), 
nonessential amino acids (NEA), penicillin and 
streptomycin were from Lonza (Lonza Milano SRL, 
Milan, Italy). Opti-MEM® Reduced Serum Medium used 
for transfection was from Life Technologies (Invitrogen, 
Milan, Italy). For cell viability determination, Cell 
Proliferation Kit I (MTT) was purchased from Roche 
Applied Science (Basel, Switzerland). MK-2206 and 
AZD6244 were provided by Selleck Chemicals (Houston, 
TX, USA). Stock solutions of MK-2206 and AZD6244 
were prepared in DMSO. Doxorubicin was obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Antibody to total 
Akt-1 was from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA) while all the other antibodies were from Cell 
Signaling Technology (Danvers, MA, USA), including an 
antibody specific for Ser473 p-Akt-1. siRNA to Akt-1 was 
from Santa Cruz Biotechnology.  
Cell culture and Western blot analysis
The HCC cell lines Mahlavu and PLC were 
maintained in DMEM medium supplemented with 
10% FBS, 2 mM L-Glutamine, 0.1 mM NEA, 100 U/
ml penicillin and 100 µg/ml streptomycin. SNU387, 
SNU449 and SNU475 cell lines were maintained in 
RPMI-1640 medium supplemented with 10% FBS, 2 
mM L-Glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. All cells were cultured in a 37°C humidified 
incubator and an atmosphere of 5% CO2 in air. Western 
Blot analysis was performed by standard methods as 
described elsewhere [44-46]. 
Real-time cell growth surveillance by cell 
electronic sensing (xCELLigence System)
Proliferation was monitored in real-time cell 
electronic sensing (xCELLigence System, Roche 
Applied Science) through gold microelectrode arrays on 
a glass substrate in the bottom of 96 E-Plates, specific 
for the system. HCC cells (2,500-20,000 cells/well in 
100 μl, depending on the cell growth) were seeded into 
16 E-Plates (Roche Applied Science) containing 100 μl 
medium/well. After 24h, 100 μl medium was discarded 
and replaced with 100 μl of fresh medium for each well. 
MK-2206 was added at the indicated concentrations 
to 200 μl of medium. In the xCELLigence System the 
changes in cell number are detected as modifications in the 
measurement of electrical impedance and are represented 
as Cell Index (CI). Since the number of cells that have 
been seeded is known, the CI is related to the quantitative 
measurement of the electrical impedance present in the 
well and it displays in plots the changes of cells that 
adhere to the conducting metals on the bottom of the 
wells. Therefore, CI values increase or decrease in parallel 
with cell growth due to the insulating properties of the cell 
membrane attached to the bottom of the well. Untreated 
cells were used to establish a reference baseline; results 
were baseline adjusted and expressed as CI normalized to 
the time point of compound administration. CI was used 
to determine also the IC50 values of MK-2206. 
Cell viability analysis 
MTT (3-[4,5-Dimethylthythiazol-2-yl]-2,5- 
Diphenyltetrazolium Bromide) assays were performed 
to assess the sensitivity of cells to drugs, as previously 
described [47-49].
Cell cycle and apoptosis analysis
Cell cycle analysis was performed using the MuseTM 
Cell Analyzer (Merck Millipore, Milan, Italy). In brief, 
after 24h of treatment, cells were harvested, centrifugedat 
300 x g for 5 min and washed once with 1X PBS. After 
fixing them with 70% ethanol for at least 3h at -20°C, cells 
were centrifuged at 300x g for 5 min, washed once with 
1X PBS and then 200 μl of Muse TM Cell Cycle reagent 
was added to each tube with an incubation of 30 min at 
room temperature in the dark. Samples were then analyzed 
according to the manufacturer’s instructions.
Moreover, analysis of apoptosis in PLC and 
Mahlavu cells was performed by Annexin-V/7-AAD-
Assay using the MuseTM Cell Analyzer. In brief, cells 
treated with increasing concentrations of MK-2206 were 
harvested by trypsinisation after 4h and 8h of treatment, 
and a 100 μl cell suspension was labeled for 20 min in the 
Oncotarget 2013; 4: 1496-15061504www.impactjournals.com/oncotarget
dark with the same volume of the MuseTM Annexin-V 
& Dead Cell reagent (Merck Millipore). Subsequently, 
quantitative detection of Annexin-V/7-AAD positive cells 
was performed with the MuseTM Cell Analyzer.
siRNA downregulation of Akt-1
Mahlavu cells were transfected in Opti-MEM® 
Reduced Serum Medium (Invitrogen) with 4μg siRNA 
Akt-1 in six-well plates using Lipofectamine 2000 
(Invitrogen), according to the manufacturer’s instructions. 
After 6h of transfection, Mahlavu cells were incubated 
for an additional 18h with MK-2206 for a total of 24h 
of transfection and then harvested for Western blotting 
analysis. The same experiment was performed using 
xCELLigence, where the cells where plated and 
transfected in 16 well xCELLigence plates.
Combined drug effects analysis
The combination effect and a potential synergy 
between MK-2206 and doxorubicin were evaluated with 
the xCELLigence System. In brief, after 24h from seeding 
in E-Plate, Mahlavu cells were treated with different 
concentrations of MK-2206 and doxorubicin, and the 
combination effects were evaluated after 48h of treatment 
by monitoring the different values of CI.
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